logo

BBLG

Bone Biologics·NASDAQ
--
--(--)
--
--(--)
1.10 / 10
Underperform

The company shows challenging fundamentals (1.1/10). Positive drivers: Net profit attributable to parent company shareholders / Net profit (%) and Cash-UP, although drawbacks are visible in Revenue-MV and Net income-Revenue. This supports a defensive investment view.

Fundamental(1.1)SentimentTechnical

Analysis Checks(3/10)

Revenue-MV
Value-0.26
Score0/3
Weight11.66%
1M Return-3.84%
ROA (%)
Value-47.48
Score0/3
Weight15.91%
1M Return-7.78%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight5.34%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight7.54%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight13.03%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-63.31
Score0/3
Weight15.91%
1M Return-7.78%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight6.02%
1M Return-1.95%
Asset-MV
Value-0.50
Score1/3
Weight2.10%
1M Return-0.63%
Cash-MV
Value-0.07
Score1/3
Weight14.31%
1M Return-5.64%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight8.17%
1M Return-2.89%
Is BBLG fundamentally strong?
  • BBLG scores 1.10/10 on fundamentals and holds a Premium valuation at present. Backed by its -51.04% ROE, 0.00% net margin, -0.34 P/E ratio, 0.42 P/B ratio, and 72.57% earnings growth, these metrics solidify its Underperform investment rating.